Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MP0533 |
| Synonyms | |
| Therapy Description |
MP0533 is a CD3-engaging Designed Ankyrin Repeat Protein (DARPin) that targets CD33, CD123, and CD70, potentially resulting in tumor cell killing and antitumor activity (Blood (2022) 140 (Supplement 1): 2251-2252). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MP0533 | MP-0533|MP 0533 | MP0533 is a CD3-engaging Designed Ankyrin Repeat Protein (DARPin) that targets CD33, CD123, and CD70, potentially resulting in tumor cell killing and antitumor activity (Blood (2022) 140 (Supplement 1): 2251-2252). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05673057 | Phase Ib/II | MP0533 Azacitidine + MP0533 + Venetoclax Azacitidine + MP0533 + Obinutuzumab + Venetoclax MP0533 + Obinutuzumab | Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome | Recruiting | NLD | LTU | FRA | CHE | 0 |